Atuka Inc.

Atuka’s lead scientists have dedicated their careers to furthering our understanding of Parkinson’s disease, advancing novel therapeutics, and alleviating the burden of those suffering from neurological disorders. Every day our team work towards a common goal: a cure for Parkinson’s, faster, through the world’s best preclinical neuroscience. For more than 20 years, we have collaborated with our partners to provide preclinical services that expand the frontiers of Parkinson’s disease research, and help make new, life-changing therapeutics a reality. Our neuroscientists have extensive preclinical experience developing therapies for numerous indications—including Parkinson’s, cognitive disorders, Alzheimer’s, ALS and other movement disorders such as dystonia and dyskinesia—across multiple modalities, including small molecules and biologics. Founded by Dr. Jonathan Brotchie in 2003, Atuka has been involved in the preclinical evaluation of more than 300 potential therapeutics, predominantly in Parkinson’s disease, of which more than 30 have progressed to clinical trials—a level of experience without equal in our field globally. Our lead scientists have collectively published more than 300 peer-reviewed, highly-cited papers, and individually possess h-indices ranging from 25 to 70. Atuka has collaborated with over 90 organizations, including large pharmaceutical and biotech companies, charitable foundations, universities, and government agencies. Over the course of more than 400 preclinical projects, targeting more than 60 mechanisms of action, we have built an extremely rich understanding of Parkinson’s disease, its causes, and potential treatments. With offices and facilities in Toronto and Suzhou, our team is diverse both in background and expertise, bringing to every one of our partner engagements a spirit of close collaboration, along with a commitment to the highest ethical standards in scientific research.